Skip to main content
. 2022 Mar 18;14(6):1567. doi: 10.3390/cancers14061567

Figure 5.

Figure 5

EGR4-S expression is regulated by HER- pathway targeted drug treatment. (A) Western blot analysis of HER2+ cell lysates treated for 24 h with increasing concentrations of TKI drugs (lapatinib, erlotinib) and (B) performed on indicated cell lysates treated over 24–48 h. (C) Western blot analysis of MDA-MB-468 breast cancer cell lysates treated with increasing concentrations of TKI drugs for 24 h (lapatinib, gefitinib, erlotinib).